country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-189660

Copy Link Print Information

PARP1/CDK12-IN-2

PARP1/CDK12-IN-2 is a selective dual PARP1/CDK12 inhibitor with an IC₅₀ of 42 nM for CDK12 and an IC₅₀ of 35 nM for PARP1. PARP1/CDK12-IN-2 inhibits CDK13. PARP1/CDK12-IN-2 induces Apoptosis and induces G2/M phase arrest. PARP1/CDK12-IN-2 exhibits anticancer activity against breast cancer and lung cancer. PARP1/CDK12-IN-2 can be used for research on triple-negative breast cancer.

For research use only. We do not sell to patients.

Formula: C₃₅H₃₇ClN₈O₄S
Molecular Weight:701.24

Storage:

Please store the product under the recommended conditions in the Certificate of Analysis.

PARP1/CDK12-IN-2 Chemical Structure

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Use of MCE Products

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- Parmacokinetics
Chemical Information
Purity & Documentation
References
Calculators
Help & FAQs
Classifications
Bioz

Biological Activity

Description

IC₅₀ & Target

^[1]

PARP1

35 nM (IC₅₀)

CDK12

42 nM (IC₅₀)

CDK13

PARP2

>10000 nM (IC₅₀)

All PARP Isoforms :

All CDK Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
HeLa	IC50	0.19 μM	Antiproliferative activity against human Hela cells assessed as viability reduction incubated 7 days by MTT assay. Antiproliferative activity against human Hela cells assessed as viability reduction incubated 7 days by MTT assay.	42632193
MIA PaCa-2	IC50	0.15 μM	Antiproliferative activity against human Miapaca-2 cells assessed as viability reduction incubated 7 days by MTT assay. Antiproliferative activity against human Miapaca-2 cells assessed as viability reduction incubated 7 days by MTT assay.	42632193
KYSE-150 cell line	IC50	0.23 μM	Antiproliferative activity against human Kyse-150 cells assessed as viability reduction incubated 7 days by MTT assay. Antiproliferative activity against human Kyse-150 cells assessed as viability reduction incubated 7 days by MTT assay.	42632193
ASPC1	IC50	0.91 μM	Antiproliferative activity against human Aspc-1 cells assessed as viability reduction incubated 7 days by MTT assay. Antiproliferative activity against human Aspc-1 cells assessed as viability reduction incubated 7 days by MTT assay.	42632193
A549	IC50	0.41 μM	Antiproliferative activity against human A549 cells assessed as viability reduction incubated 7 days by MTT assay. Antiproliferative activity against human A549 cells assessed as viability reduction incubated 7 days by MTT assay.	42632193
MDA-MB-231	IC50	0.23 μM	Antiproliferative activity against human MDA-MB-231 cells assessed as viability reduction incubated 7 days by MTT assay. Antiproliferative activity against human MDA-MB-231 cells assessed as viability reduction incubated 7 days by MTT assay.	42632193
SK-BR-3	IC50	0.06 μM	Antiproliferative activity against human SK-BR-3 cells assessed as viability reduction incubated 7 days by MTT assay. Antiproliferative activity against human SK-BR-3 cells assessed as viability reduction incubated 7 days by MTT assay.	42632193
MCF7	IC50	0.30 μM	Antiproliferative activity against human MCF-7 cells assessed as viability reduction incubated 7 days by MTT assay. Antiproliferative activity against human MCF-7 cells assessed as viability reduction incubated 7 days by MTT assay.	42632193
Hs-578T	IC50	0.15 μM	Antiproliferative activity against human HS578T cells assessed as viability reduction incubated 7 days by MTT assay. Antiproliferative activity against human HS578T cells assessed as viability reduction incubated 7 days by MTT assay.	42632193

In Vitro

Anti-cancerApoptosisOthers

Anti-cancer

PARP1/CDK12-IN-2 (7 days) inhibits the proliferation of nine cancer cell lines, with IC₅₀ values ranging from 0.06 to 0.91 µM, and an IC₅₀ value of 0.23 µM against MDA-MB-231^[1].
PARP1/CDK12-IN-2 (0-300 nM) concentration-dependently inhibited colony formation of MDA-MB-231, MCF-7, and A549 cells, and completely inhibited the growth of MDA-MB-231 and MCF-7 at 300 nM^[1].

Apoptosis

PARP1/CDK12-IN-2 (0.3-3 µM) induces apoptosis and G2/M phase arrest in MDA-MB-231 cells, with Western blot changes observed at 0.3-3 µM^[1].

Others

PARP1/CDK12-IN-2 (Compound 20b) is a dual CDK12/PARP1 inhibitor with an IC₅₀ value of 42 nM for CDK12 and an IC₅₀ value of 35 nM for PARP1, and is inactive against PARP2 (>10000 nM)^[1].
PARP1/CDK12-IN-2 (200 nM) potently inhibits CDK12/13 and exhibits moderate to weak activity against CDK1, CDK4, CDK6, CDK8, CDK18, and CDK19^[1].
PARP1/CDK12-IN-2 exhibits moderate in vitro metabolic stability in mouse liver microsomes, T_1/2 = 123 min, CL_int = 0.0282 mL/min/mg^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Related Protocols :

Parmacokinetics

Species	Dose	Route	CL_{_obs}	T_1/2	AUC_last	AUC_inf	MRT_{INF_obs}	V_d
Rat^[1]	5 mg/kg	i.v.	16.2 mL/min/kg	1.41 h	5325 ng·h/mL	5336 ng·h/mL	0.281 h	1.92 L/kg

Chemical Information

Molecular Weight 701.24
Formula C₃₅H₃₇ClN₈O₄S
SMILES

NC(C1=CC=CC2=C1N=C(C3=CC=C(N([C@@H]4CC[C@@H](NC5=NC=C(Cl)C(NC6=CC=CC=C6S(C(C)C)(=O)=O)=N5)CC4)C(C)=O)C=C3)N2)=O
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Handling Instructions (2659 KB)

References

[1]. Zhong ZJ, et al. Discovery of novel dual-target CDK12/PARP1 inhibitors for the treatment of triple-negative breast cancer. Eur J Med Chem. 2026 Aug 20;319:119255.

Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

Keywords

MOQ

Minimum order quantity

100 mg

Get Quote In-stock

Other size

Get Quote

Amount: USD 0.00

Biological Activity
- Description
- IC₅₀ & Target
- In Vitro
Chemical Information
Purity & Documentation
References

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

PARP1/CDK12-IN-2

All PARP Isoforms

All CDK Isoforms